company background image
RLFT.F logo

Relief Therapeutics Holding OTCPK:RLFT.F Stock Report

Last Price

US$4.65

Market Cap

US$61.1m

7D

-5.1%

1Y

120.9%

Updated

23 Dec, 2024

Data

Company Financials

Relief Therapeutics Holding SA

OTCPK:RLFT.F Stock Report

Market Cap: US$61.1m

RLFT.F Stock Overview

A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. More details

RLFT.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Relief Therapeutics Holding SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Relief Therapeutics Holding
Historical stock prices
Current Share PriceCHF 4.65
52 Week HighCHF 7.66
52 Week LowCHF 1.10
Beta-14.7
1 Month Change-15.84%
3 Month Change66.07%
1 Year Change120.90%
3 Year Change-79.42%
5 Year Changen/a
Change since IPO-70.94%

Recent News & Updates

Recent updates

Shareholder Returns

RLFT.FUS BiotechsUS Market
7D-5.1%-3.8%-2.7%
1Y120.9%-2.6%23.4%

Return vs Industry: RLFT.F exceeded the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: RLFT.F exceeded the US Market which returned 23.4% over the past year.

Price Volatility

Is RLFT.F's price volatile compared to industry and market?
RLFT.F volatility
RLFT.F Average Weekly Movement25.4%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: RLFT.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RLFT.F's weekly volatility has increased from 19% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201349n/awww.relieftherapeutics.com

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.

Relief Therapeutics Holding SA Fundamentals Summary

How do Relief Therapeutics Holding's earnings and revenue compare to its market cap?
RLFT.F fundamental statistics
Market capUS$61.09m
Earnings (TTM)-US$51.78m
Revenue (TTM)US$9.63m

6.3x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RLFT.F income statement (TTM)
RevenueCHF 8.60m
Cost of RevenueCHF 2.70m
Gross ProfitCHF 5.90m
Other ExpensesCHF 52.13m
Earnings-CHF 46.24m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.69
Gross Margin68.56%
Net Profit Margin-537.79%
Debt/Equity Ratio0.02%

How did RLFT.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Relief Therapeutics Holding SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexandre MüllerResearch Dynamics
Bob PoolerValuationLAB AG